Vanderbilt University Purchases Shares of 13,780 Boston Scientific Corporation $BSX

Vanderbilt University bought a new stake in Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 13,780 shares of the medical equipment provider’s stock, valued at approximately $1,480,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. 1248 Management LLC acquired a new position in Boston Scientific during the 1st quarter worth about $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $27,000. Sound Income Strategies LLC raised its position in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $37,000. Finally, Activest Wealth Management raised its position in shares of Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 373 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Raymond James Financial increased their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 24th. Barclays increased their target price on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday. Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Needham & Company LLC reissued a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a research note on Wednesday. Finally, Robert W. Baird increased their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific has an average rating of “Buy” and an average target price of $120.79.

Boston Scientific Price Performance

Shares of BSX opened at $96.36 on Friday. The stock has a market capitalization of $142.78 billion, a P/E ratio of 57.36, a P/E/G ratio of 2.31 and a beta of 0.61. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a 50 day moving average of $103.10 and a 200-day moving average of $102.06. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business’s quarterly revenue was up 22.8% on a year-over-year basis. During the same period last year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.